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Background: Neuroinflammation occurs in insulted regions of the brain and may be due to reactive oxygen
species (ROS), nitric oxide (NO), cytokines, and chemokines produced by activated glia. Excessive production of
neurotoxic molecules causes further neuronal damage. Low levels of vitamin D3 are a risk factor for various
brain diseases.
Methods: Using the bacterial endotoxin, lipopolysaccharide (LPS), to induce neuroinflammation in primary
cortical neuron-glia cultures, we investigated how 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) affected
neuroinflammation.
Results: LPS (100 ng/ml) induced the accumulation of nitrite and the production of ROS, interleukin (IL)-6, and
macrophage inflammatory protein (MIP)-2 in time-dependent manners. Inhibition of p38 and extracellular
signal-regulated kinase (ERK) but not c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK)
by 20 μM of SB203580, PD98059, and SP600125, significantly reduced LPS-induced ROS production, NO
accumulation, and inducible NO synthase (iNOS) expression, respectively. LPS-induced IL-6 and MIP-2 were
significantly attenuated by inhibition of p38, ERK, and JNK MAPK. Cotreatment with 1,25(OH)2D3 attenuated
LPS-induced ROS production, NO accumulation, and iNOS expression in concentration-dependent manners.
1,25(OH)2D3 also reduced LPS-induced production of IL-6 and MIP-2. Similarly, iNOS, IL-6, and MIP-2 mRNA
expression in cells treated with LPS significantly increased, whereas this effect was attenuated by 1,25(OH)2D3.
Moreover, LPS-induced phosphorylation of p38, ERK, and JNK MAPK was significantly inhibited by 1,25(OH)2D3.
Conclusions: Our findings indicate that 1,25(OH)2D3 reduced the LPS-stimulated production of inflammatory
molecules in neuron-glia cultures by inhibiting MAPK pathways and the production of downstream
inflammatory molecules. We suggest that 1,25(OH)2D3 can be used to alleviate neuroinflammation in various
brain injuries.Introduction
1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3) is a secosteroid
hormone, synthesized through a multistep process, which
begins in the skin and is completed in the kidneys.
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article, unless otherwise stated.which has no biological activity until its conversion to the
active form, 1,25-(OH2)D3 [1]. The activated vitamin D
metabolite has many roles in regulating homeostasis (e.g.,
calcium homeostasis and maintenance) throughout the
body. 1,25-(OH)2D3 has effects on the classic target organs
(e.g., bones, intestines, and kidneys) and stimulates cal-
cium transport from these organs to the blood. A growing
body of evidence has demonstrated that 1,25-(OH)2D3
plays an important role in non-classical actions such as
regulating immune function [2]. It is known that 1,25-
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(OH)2D3 was shown to regulate neurotrophic factors
in the brain, including nerve growth factors (NGFs)
[4], neurotrophin 3 (NT3) [5], and glial cell line-
derived neurotrophic factor (GDNF) [6]. Additionally,
1,25-(OH)2D3 increases expressions of microtubule-
associated protein-2, growth-associated protein-43 [7],
and neurite outgrowth [8] in cultured neurons, indi-
cating that 1,25-(OH)2D3 may also affect neuronal
plasticity processes.
Clinical studies suggested that a vitamin D insuffi-
ciency is associated with an increased risk of brain in-
sults such as Alzheimer’s disease (AD) [9], Parkinson’s
disease [10], and ischemic brain injury [6]. In animal
studies, a vitamin D deficiency exacerbated stroke brain
injury and dysregulated ischemia-induced inflammation
[11], whereas administration of 1,25-(OH)2D3 reduced
ischemia-induced brain damage through upregulating
GDNF expression [6]. Pretreatment with 1,25-(OH)2D3
attenuated hypokinesia and dopaminergic neurotoxicity
induced by 6-OHDA in rats [12]. Moreover, 1,25-(OH)2D3
increased secretion of anti-inflammatory cytokines and re-
duced secretion of proinflammatory cytokines [4, 5, 13],
suggesting that 1,25-(OH)2D3 may be neuroprotective and
may regulate neuroinflammation in the brain. However,
the underlying mechanisms of vitamin D’s effect on
neuroinflammation remain unclear.
Neuroinflammation is a common mechanism and
plays a crucial role in the pathogenesis of various nerve
diseases. Initiation of a neuroinflammatory response in-
volves a complex interplay of glia. Activated glial cells,
mainly astrocytes and microglia, are thus histopatho-
logical hallmarks of neurologic diseases. Inflammatory
mediators (e.g., nitric oxide (NO), reactive oxygen spe-
cies (ROS), proinflammatory cytokines, and chemokines)
released by activated glia are neurotoxic and can cause
neuronal damage [14]. It is known that lipopolysacchar-
ide (LPS), a gram-negative bacterial cell wall endotoxin,
can activate glia through Toll-like receptors, triggering
downstream signaling, such as mitogen-activated protein
kinases (MAPKs). Three major MAPK subfamilies have
been described: p38, extracellular signal-regulated kinase
(ERK), and c-Jun N-terminal kinase (JNK). Activation of
MAPK pathways by LPS initiates neuroinflammatory
cascades characterized by activation of glia and increas-
ing production of inflammatory mediators including
ROS, NO, cytokines, and chemokines [15–17]. Therefore,
controlling activated glia can be a therapeutic strategy for
neuroinflammation.
Studying the protective roles of antioxidant com-
pounds in inhibiting the inflammatory response in brain
diseases is an important vista for further research and
clinical applications. Using cortical neuron-glia cultures,
we investigated how 1,25-(OH)2D3 affected LPS-inducedneuroinflammatory responses, by exploring whether the
effects of 1,25-(OH)2D3 are mediated through MAPK
pathways.
Materials and methods
Chemical reagents and antibodies
1,25-(OH)2D3 (SI-D1530) and LPS (L3129) were pur-
chased from Sigma-Aldrich (St. Louis, MO). The p38
MAPK inhibitor, SB203580, ERK inhibitor, PD98059,
JNK inhibitor, SP600125, iNOS, and β-actin were pur-
chased from Calbiochem (San Diego, CA). Antibodies
against ERK, p38, JNK, phosphorylated (p)-p38, p-ERK
(p-p42/p44), and p-JNK (p-p46/p54) were purchased
from Cell Signaling Technology (Beverly, MA). Anti-
bodies against microtubule-associated protein-2 (MAP-2)
and glial fibrillary acid protein (GFAP) were purchased
from Chemicon (Temecula, CA). Antibody against ED1
was purchased from Serotec (Bicester, UK). Antibodies
against oligodendrocyte marker 4 (O4), fibronectin 1
(FN1), and rat endothelial cell antigen (RECA-1) were pur-
chased from R&D systems (Minneapolis, MN), Bioworld
Technology (MN, USA), and Abcam (Cambridge, MA),
respectively.
Primary rat cortical neuron-glia cultures
Primary neuron-glia cultures were prepared from the
cerebral cortex of 1-day-old neonatal Sprague–Dawley
rats, as previously described [18–31]. All animal proce-
dures were approved by the Institutional Animal Care
and Use Committee of Taipei Medical University (Taipei,
Taiwan) (permit no.: LAC-101-0249). These procedures
were performed according to the National Institutes of
Health Guidelines for the Care and Use of Laboratory
Animals. After the rats were sacrificed, their brains were
quickly removed aseptically, and the blood vessels and
meninges were discarded. Cerebral cortices were dis-
sected under sterile conditions and kept on ice in Hank’s
solution (without Ca2+ or Mg2+). Subsequently, cortical
cells were dissociated by trituration using a pipette. Cells
were centrifuged (1500 rpm for 5 min) and resuspended
in 10 % fetal bovine serum/Dulbecco’s modified Eagle’s
medium (Gibco BRL, Grand Island, NY). To each well
of 24-well culture plates was seeded 5 × 105 cells in
0.5 ml of culture medium. Cells were incubated at 37 °C
and 5 % CO2 at a humidity of 95 % and used for ex-
periments starting on day 14 of cultivation in vitro.
The percentage cell composition was determined by
immunostaining, followed by cell counting. The
neuron-glia cultures consisted of approximately 35 %
neurons, 54 % astrocytes, and 6 % microglia. In
addition, cultures also consisted of approximately 4 %
of fibroblasts and a small percentage (<1 %) of other
cells including oligodendrocytes, and endothelial cells
(pictures not shown).
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Cultures were fixed in 4 % paraformaldehyde, as previ-
ously described [18]. Background staining was reduced
by blocking nonspecific binding sites with 10 % goat
serum for 1 h at room temperature. After washing with
phosphate-buffered saline (PBS), endogenous peroxidase
activity was quenched by incubation with a 3 % H2O2
solution in PBS. Cultures were washed again and then
incubated overnight with the appropriate primary anti-
bodies (rabbit anti-MAP-2, 1:500, Chemicon; rabbit
anti-GFAP, 1:1000, Chemicon; mouse anti-ED1, 1:500,
Serotec; mouse anti-O4, 1:300, R&D system; rabbit-anti
fibronectin 1, 1:500, Bioworld Technology; mouse-anti
RECA-1, 1:300, Abcam) at 4 °C. Cells were washed and
visualized using the avidin-biotin peroxidase complex
method (ABC Elite kit; Vector Laboratories, Burlin-
game, CA). Images were viewed on an inverted Olym-
pus IX 70 microscope (Tokyo City, Japan) equipped
with a cooled CCD camera and SPOT advanced soft-
ware (Diagnostic Instruments, Sterling Heights, MI).
Cell-type identification and counting
Types of cells present in the culture were identified by im-
munocytochemical staining using cell-specific markers
(MAP-2 for neurons, GFAP for astrocytes, ED1 for micro-
glia, FN1 for fibroblasts, O4 for oligodendrocytes, and
RACE-1 for endothelial cells). Images of immunostained-
positive cells in each well (in five randomly selected fields
with a calibrated area) were captured as digital micro-
graphs, and cells were counted by an observer who
was blinded to our study and confirmed by the experi-
ment operator.
Measurement of ROS
ROS production was detected using the fluorochrome,
2′,7′-dichlorofluorescin diacetate (DCF-DA). Treated
cells were incubated with 30 μM DCF-DA in cultured
medium for 20 min at 37 °C. After incubation, the cul-
ture medium was removed, and then 500 μl of culture
medium was added to each culture well. Plates were
read with a fluorometric microplate reader at 485/500 nm
[23]. Production of ROS was calculated as the maximum
DCF fluorescence following incubation (20 min). The
value of DCF fluorescence is expressed in arbitrary
fluorescence units (AU).
Determination of NO accumulation
Nitrite accumulation was measured using the Griess re-
action in culture media. After treatment, culture
medium was collected for measurement of nitrite.
Briefly, 50 μl of culture medium was mixed with an
equal volume of Griess reagent. The absorbance was
detected at 540 nm by a microplate reader (Molecular
Devices, Menlo Park, CA).Determination of IL-6 and macrophage inflammatory
protein (MIP)-2 release
Levels of IL-6 and MIP-2 secreted into the culture media
were measured by enzyme-linked immunosorbent assay
(ELISA) kits (BioSource International) according to the
manufacturer’s protocol.
Western blotting
Whole cell lysates were prepared from cultured neur-
onal/glial cells after 24 h of desired treatments. Treated
cells were harvested, washed with PBS, and lysed in pro-
tein extraction buffer (Mammalian Cell-PE LBTM, Geno
Technology) containing protease and phosphatase inhib-
itors (Complete Mini, Roche Diagnostics, Indianapolis,
IN). Cell debris was removed by centrifugation at
12,000 rpm for 15 min at 4 °C, and the supernatant was
collected for storage at −80 °C or to perform a Western
blot analysis. Equal amounts of protein were separated
on 10~15 % sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins were electro-
blotted onto polyvinylidene difluoride membranes for
120 min under 100 V (PerkinElmer Life Sciences). Mem-
branes were blocked with 5 % non-fat milk for 1 h, and
then incubated overnight at 4 °C with the indicated anti-
bodies, including those for inducible NO synthase
(iNOS), p38, phosphorylated (p)-p38, p42/44, p-p42/44,
p46/54, and p-p46/54 (1:1000 dilution) followed by an
appropriate secondary antibody (at a 1:2 × 104 dilution)
for 1 h at room temperature. Signals were visualized
using enhanced chemiluminescent detection reagents
(PerkinElmer Life Sciences). The membrane was then
stripped and reprobed with an antibody specific for β-
actin (at a 1:104 dilution) to ensure the accuracy of each
loading. The protein signal intensity was quantified by a
BioImaging System (Level Biotechnology) and normal-
ized with the corresponding β-actin intensity.
Real-time reverse-transcription polymerase chain reaction
(RT-PCR) assay
Total RNA was extracted from treated cells using the
TRIzol® reagent (Invitrogen Life Technologies, Paisley,
Scotland) according to the manufacturer’s protocol.
Three micrograms of total RNA was reverse-transcribed
into complementary (c)DNA using the Rever Tra Ace-α
First-strand cDNA Synthesis Kit (TOYOBO Life Science,
Japan). The resulting cDNA was incubated with the
Rotor-Gene SYBR Green kit (QIAGEN Biosystems, CA)
and primers for iNOS (sense, 5′-TTCTTTGCTTCTGTG
CTAATGC-3′ and antisense, 5′-ATACTGTTCCATGCA
GACAACC-3′); IL-6 (sense, 5′-TTCTTGGGACTGATG
TTGTTGAC-3′ and antisense, 5′-AATTAAGCCTCCGA
CTTGTGAAG-3′); MIP-2 (sense, 5′-AAACTGCACCCA
GGAAGCC-3′ and antisense, 5′-ACAGTGAGCTGGCC
AATGC-3′); and β-actin (sense, 5′-GACCCAGATCATG
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ACACTACCTGAG-3′). For the semiquantitative analysis,
we performed 40 amplification cycles (of denaturation at
95 °C for 5 s and annealing at 60 °C for 10 s) on a Rotor-
Gene Q PCR Detection System (QIAGEN Biosystems). A
melting curve analysis and sequencing data were used to
confirm the specificity of the PCR products. Levels of
iNOS, IL-6, and MIP-2 messenger (m)RNAs were normal-
ized to those of β-actin and were then expressed as values
relative to the control using the comparative threshold
cycle (Ct) method.
3-(4,5-Dimethylthianol-2-yl)-2,5 diphenyl tetrazolium
bromide (MTT) reduction assay
To examine cell viability, a colorimetric MTT reduction
assay was performed as previously described [24]. After
a 2-h treatment, the MTT reagent (0.5 mg/ml MTT in
PBS) was added to each culture well, and cultured cells
were incubated at 37 °C for 40 min. The culture medium
was then aspirated from each well, and cells were dis-
solved by adding DMSO. The absorbance was measured
at a test wavelength of 570 nm and a reference wave-
length of 630 nm using a microplate reader (Molecular
Devices).
Measurement of lactate dehydrogenase (LDH) release
Cytotoxicity was detected in culture media using an
assay of LDH release, as an index of cell injury [18, 25].
LDH activity (units/min) was calculated from the slope
of the decrease in the optical density at 340 nm over a
3-min period. The level of LDH was expressed as a per-
centage of values relative to PBS-treated control (Cont.)
cultures.
Data analysis
All values are presented as the mean ± standard error of
the mean (SEM). Experimental data were assessed usingFig. 1 Effect of lipopolysaccharide (LPS) on reactive oxygen species (ROS) p
inflammatory protein (MIP)-2 production. Cultured cells were treated with L
cells was detected by DCF fluorescence. The y-axis of the graph is expresse
medium was collected to analyze levels of nitrite accumulation. c The cultu
expressed as the mean ± SEM (n = 5 in each group). *p < 0.05, **p < 0.01, **a one-way analysis of variance (ANOVA) followed by
the Newman-Keuls’ test using the SigmaStat program
(Jandel Scientific, San Rafael, CA). Significance was set
at p < 0.05.
Results
LPS-induced ROS production, nitrite accumulation, and
the release of proinflammatory mediators
To examine whether LPS elicited neuroinflammatory re-
sponses in cultured neurons/glia, we first examined the
time course of LPS-induced ROS production, nitrite ac-
cumulation, and the release of IL-6 (a cytokine) and
MIP-2 (a chemokine). As shown in Fig. 1a, treating cells
with LPS (100 ng/ml) for the indicated periods (3, 6, 9,
12, and 24 h) induced ROS production in a time-
dependent manner. ROS production significantly in-
creased in cultured cells exposed to LPS for 6 h (p < 0.05)
and continued to increase from 12 to 24 h (p < 0.01 and
p < 0.001, respectively). NO production, as reflected by
nitrite accumulation, significantly increased in cultured
cells exposed to LPS for 12 h (p < 0.01) and continued
to increase from 12 to 24 h (p < 0.001; Fig. 1b). Additionally,
IL-6 significantly increased in cultured cells exposed to
LPS for 6 h (p < 0.05) and remained elevated for up to
24 h (p < 0.001; Fig. 1c). Similarly, we also found that
MIP-2 increased in cultured cells exposed to LPS for 9 h
(p < 0.05) and remained elevated for up to 24 h (p < 0.001;
Fig. 1c). As expected, LPS successfully initiated a neu-
roinflammatory response in our neuronal/glial coculture
system.
Involvement of MAPK signaling pathways in LPS-induced
production of proinflammatory mediators
To examine whether MAPKs (e.g., p38, ERK, and JNK)
are involved in the production of LPS-initiated proin-
flammatory mediators, we treated cells with various con-
centrations (10 and 20 μM) of MAPK inhibitors androduction, nitrite accumulation, and interleukin (IL)-6 and macrophage
PS (100 ng/ml) for the indicated time periods. a ROS production by
d in DCF fluorescent arbitrary units (AU). b After treatment, the culture
re medium was collected to analyze levels of IL-6 and MIP-2. Data are
*p < 0.001 vs. the control (Cont.)
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production, nitrite accumulation, iNOS expression, and
IL-6 and MIP2 production. In the absence of LPS, neither
SB203580 (a p38 inhibitor), PD98059 (an ERK inhibitor),
nor SP600125 (a JNK inhibitor) at 20 μM significantly
affected ROS production (Fig. 2a). Cotreatment of 10
or 20 μM SB203580 with LPS for 24 h significantly at-
tenuated LPS-induced ROS production; and 20 μM
SB203580 more completely inhibited ROS production
compared to 10 μM; however, the difference was non-
significant. Cotreatment of 20 μM but not 10 μM
PD98059 with LPS produced a significant reduction in
ROS (p < 0.05). However, cotreatment of 10 or 20 μM
JNK with LPS did not reduce ROS production (Fig. 2a).
Figure 2b shows that cells treated with 10 or 20 μM
SB203580 and LPS exhibited significantly attenuated
nitrite accumulation, and 20 μM more completely
inhibited this accumulation compared to 10 μM. Both
SB203580 and PD98059 but not SP600125 at 20 μM
significantly reduced LPS-induced nitrite accumulation
(p < 0.001). Regarding iNOS induction, treatment with
20 μM of each inhibitor (SB203580, PD98059, and
SP600125) alone had no effect (data not shown). Western
blot analyses indicated that cotreatment with SB203580
or PD98059 and LPS for 24 h significantly attenuated
the level of LPS-induced iNOS expression (p < 0.001Fig. 2 Effect of mitogen-activated protein kinase (MAPK) inhibitors on lipop
nitrite accumulation, and inducible nitric oxide synthase (iNOS) expression.
20 μM) of SB203580 (a p38 inhibitor), PD98059 (an extracellular signal-regu
(JNK) inhibitor), and then exposed to LPS (100 ng/ml) for 24 h. a ROS prod
graph is expressed in DCF fluorescent arbitrary units (AU). b The culture m
treatment, cells were harvested for a Western blot analysis. Levels of iNOS
induced by LPS was set to 100 % expression. Data are expressed as the me
+p < 0.05, ++p < 0.01, +++p < 0.001 vs. LPSand p < 0.01, respectively), whereas cells cotreated with
the JNK inhibitor and LPS exhibited no effect (Fig. 2c).
Additionally, cotreating cells with SB203580, PD98059,
or SP600125 and LPS for 24 h significantly attenuated
the release of IL-6 (p < 0.001) and MIP-2 (p < 0.001)
compared to the release in cultures treated with LPS
alone (Fig. 3). Levels of IL-6 and MIP-2 production in
cultures treated with SB203580, PD98059, or SP600125
alone did not significantly differ from those produced in
control cultures (data not shown). These results suggest
that activation of p38, ERK, and JNK MAPKs is involved
in LPS-induced ROS production, nitrite accumulation,
and proinflammatory mediator release.
1,25-(OH)2D3 suppressed LPS-induced ROS production,
nitrite accumulation, iNOS expression, and the release of
inflammatory mediators without causing cell death
1,25-(OH)2D3, a potent functional hormone, is one of
the important nuclear steroid transcription regulators
that regulate the transcription of a large number of
genes. We examined whether 1,25-(OH)2D3 could at-
tenuate an experimental neuroinflammatory response
produced using LPS in a neuron-glia culture model.
Exposing cells to LPS for 24 h significantly enhanced
ROS production (p < 0.001, Fig. 4a), nitrite accumulation
(p < 0.001, Fig. 4b), iNOS expression (p < 0.001, Fig. 4c),olysaccharide (LPS)-induced reactive oxygen species (ROS) production,
Cultured cells were treated with various concentrations (10 and
lated kinase (ERK) inhibitor), or SP600125 (a c-Jun N-terminal kinase
uction by cells was detected by DCF fluorescence. The y-axis of the
edium was collected to analyze levels of nitrite accumulation. c After
were normalized to β-actin, and then quantified. The iNOS expression
an ± SEM (n = 4 or 5 in each group). ***p < 0.001 vs. the control (Cont.);
Fig. 3 Effect of mitogen-activated protein kinase (MAPK) inhibitors
on lipopolysaccharide (LPS)-induced interleukin (IL)-6 and macrophage
inflammatory protein (MIP)-2 production. Cultured cells were treated
for 24 h with 20 μM SB203580, 20 μM PD98059, or 20 μM SP600125
and were then exposed to LPS (100 ng/ml). The culture medium was
collected to analyze levels of IL-6 and MIP-2. Data are expressed as the
mean ± SEM (n= 4 in each group). ***p < 0.001 vs. the control (Cont.);
+++p < 0.001 vs. LPS
Fig. 5 Effect of 1,25(OH)2D3 on lipopolysaccharide (LPS)-induced
interleukin (IL)-6 and macrophage inflammatory protein (MIP)-2
release. Cultured cells were untreated (PBS) or treated with
1,25(OH)2D3 (100 nM), LPS (100 ng/ml), or 1,25(OH)2D3 plus LPS
for 24 h, and then the culture medium was collected to analyze
levels of IL-6 and MIP-2. Data are expressed as the mean ± SEM
(n = 4 in each group). ***p < 0.001 vs. the control (Cont.); ++p < 0.01,
+++p < 0.001 vs. LPS
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pared to those of control cultures. 1,25(OH)2D3 (100 nM)
alone exerted no effects. Cotreating cells with 10 or
100 nM but not 1 nM of 1,25(OH)2D3 and LPS signifi-
cantly attenuated levels of ROS production (p < 0.001,
Fig. 4a). Similarly, cotreatment with 1, 10, or 100 nM of
1,25(OH)2D3 and LPS for 24 h significantly reduced nitrite
accumulation (p < 0.001, Fig. 4b) and levels of iNOS ex-
pression (p < 0.001, Fig. 4c) in a concentration-dependent
manner. Moreover, cotreating cells with 100 nM ofFig. 4 Effects of 1,25(OH)2D3 on levels of lipopolysaccharide (LPS)-induced
inducible nitric oxide synthase (iNOS) expression. Cultured cells were untre
various concentration of 1,25(OH)2D3 (1, 10, or 100 nM) plus LPS for 24 h. a
of the graph is expressed in DCF fluorescent arbitrary units (AU). b The cul
c After treatment, cells were harvested to analyze levels of iNOS protein
to β-actin and then quantified. iNOS expression induced by LPS was set
in each group). *p < 0.05, **p < 0.01, ***p < 0.001 vs. the control (Cont.); +1,25(OH)2D3 significantly reduced LPS-induced IL-6 and
MIP-2 production (p < 0.001, Fig. 5). Regarding protein ex-
pressions, levels of iNOS (Fig. 6a), IL-6, and MIP-2 pro-
teins (Fig. 6b) were significantly reduced in cells exposed to
1,25(OH)2D3 plus LPS for 24 h. These results indicated
that 1,25(OH)2D3 attenuated LPS-induced iNOS, IL-6, and
MIP-2 expressions at both the protein and mRNA levels.
We also monitored cell viability using an MTT reduc-
tion assay and confirmed it using LDH measurements.
Results from both the MTT reduction assay and LDH
measurements showed that the viability of cultured cellsreactive oxygen species (ROS) production, nitrite accumulation, and
ated (PBS) or treated with 1,25(OH)2D3 (100 nM), LPS (100 ng/ml), or
ROS production by cells was detected by DCF fluorescence. The y-axis
ture medium was collected to analyze levels of nitrite accumulation.
expression using Western blotting. Levels of iNOS were normalized
to 100 % expression. Data are expressed as the mean ± SEM (n = 5
++p < 0.001 vs. LPS
Fig. 6 Effect of 1,25(OH)2D3 on lipopolysaccharide (LPS)-induced
inducible nitric oxide synthase (iNOS), interleukin (IL)-6, and
macrophage inflammatory protein (MIP)-2 gene expressions.
Cultured cells were untreated (PBS) or treated with 1,25(OH)2D3
(100 nM), LPS (100 ng/ml), or 1,25(OH)2D3 plus LPS for 24 h. After
treatment, cultured cells were harvested to conduct an RT-PCR
assay of iNOS (a), IL-6, and MIP-2 (b) mRNA levels. Expression levels
of iNOS, IL-6, and MIP-2 mRNAs were normalized to β-actin. Data
are expressed as the mean ± SEM (n = 4 in each group). **p < 0.01
and ***p < 0.001 vs. the control (Cont.); ++p < 0.01, +++p < 0.001 vs. LPS
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did not significantly differ from that of PBS-treated cells
(Fig. 7a). The MTT assay revealed that cotreatment with
1,25(OH)2D3 and LPS non-significantly affected cell via-
bility compared to that of control cultures. Compared to
the medium control, no significant differences existed in
levels of LDH release (an indicator of cell death) when
1,25(OH)2D3 and LPS were simultaneously added, indi-
cating that the 1,25(OH)2D3 concentration used in this
study was not toxic to cells. Determination of LDH re-
lease and the MTT reduction test might not be sufficient
to study cell damage. Therefore, cytotoxicity was further
assessed by immunocytochemical staining, and we subse-
quently counted the number of positive cells with anti-
bodies against MAP-2 (a neuron marker), GFAP (an
astrocyte marker), and ED1 (a microglia marker), respect-
ively. Exposure of cortical neuron-glia cultures to either1,25(OH)2D3, LPS, or a combination of 1,25(OH)2D3 and
LPS for 24 h did not alter the number of MAP-2-positive
cells or the morphology of those cells compared to control
cultures. Numbers of GFAP-positive and ED1-positive cells
did not significantly differ among control culture and cul-
tures treated with 1,25(OH)2D3, LPS, or a combination of
1,25(OH)2D3 and LPS (Fig. 7b, c). Exposure of cells to
1,25(OH)2D3 alone retained both astrocytes and microglia
resting morphologies. However, LPS treatment changed
the morphologies of astrocytes and microglia from those
representing the resting state to those representing the ac-
tive state. Activated astrocytes had an enlarged size and a
massive accumulation of GFAP-positive filaments; ED1-
positive microglia changed from the resting state, which
exhibits a small soma and long cytoplasmic processes, to
the activated form, which is characterized by an amoeboid
appearance. A combination of 1,25(OH)2D3 and LPS atten-
uated the LPS-induced morphological changes in astro-
cytes and microglia. Taken together, our results suggest
that the selected concentration of 1,25(OH)2D3 (100 nM)
effectively reduced the LPS-initiated neuroinflammatory
response without damaging cells.
1,25(OH)2D3 inhibited LPS-stimulated activation of MAPK
signaling
To examine whether the antioxidant and anti-inflammatory
effects of 1,25(OH)2D3 were mediated by inhibition of
LPS-induced MAPK activation, we examined the effects
of simultaneous treatments with LPS for 180 min using
various combinations of the p38 inhibitor, SB203580,
ERK inhibitor, PD98059, JNK inhibitor, SP600125, and
1,25(OH)2D3. Western blot results showed that LPS-
stimulated phosphorylation of p38, p42/44 (ERK), and
p46/54 (JNK) was significantly inhibited by SB203580
(p < 0.01, Fig. 8a), PD98059 (p < 0.001 for p-p42 and p <
0.05 for p-p44; Fig. 8b), and SP600125 (p < 0.001 for both
p-p46 and p-p54; Fig. 8c), respectively. Cultured cells
cotreated with 1,25(OH)2D3 and LPS exhibited signifi-
cantly attenuated p-p38 (p < 0.001, Fig. 8a), p-p42/44 (p <
0.05 for both p-p42 and p-p44; Fig. 8b), and p-p46/54
levels (p < 0.001 for both p-p46 and p-p54; Fig. 8c). Activa-
tion of the phosphorylation of p38, ERK, and JNK did not
significantly differ among control cultures and those
treated with MAPK inhibitors or 1,25(OH)2D3 alone (data
not shown). These results suggest that 1,25(OH)2D3
suppressed the production of LPS-induced inflamma-
tory mediators by inhibiting the p38, ERK, and JNK
MAPK pathways.
Discussion
Glial cells, namely astrocytes and microglia, are the
most abundant cells in the brain and play pivotal roles
in protecting neurons from harmful insults. Activation
of glia following infection or neuronal injury causes
Fig. 7 A lack of 1,25(OH)2D3 affected cell survival and cell death. Cultured cells were untreated (PBS) or treated with 1,25(OH)2D3 (100 nM), LPS (100 ng/ml),
or 1,25(OH)2D3 plus LPS for 24 h. a After treatment, cultured cells were used for an MTT reduction assay. The culture medium was collected for lactate
dehydrogenase (LDH) measurement. Cytotoxicity was assayed based on levels of LDH activity in the culture medium. MTT reduction or LDH release data
are expressed as a percentage of values relative to control (Cont.) cultures. Data are expressed as the mean± SEM (n=4 in each group). b After treatment,
cultured cells were fixed, and then immunocytochemically stained with an antibody against a specific cell marker (MAP-2, GFAP, or ED1). Representative
photomicrographs show cultures stained with antibodies to identify neurons (MAP-2-positive cells; a), astrocytes (GFAP-positive cells; b), and microglia
(ED1-positive cells; c). Arrows indicate activated glial cells. c Cell counts of MAP-2-, GFAP-, and ED1-positive cells in cultures exposed to either PBS, 1,25(OH)2D3,
LPS, or 1,25(OH)2D3 plus LPS for 24 h. Data are the mean± SEM from three independent experiments
Fig. 8 Mitogen-activated protein kinase (MAPK) inhibitors and 1,25(OH)2D3 inhibited lipopolysaccharide (LPS)-induced phosphorylation of p38, extracellular
signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK). Cultured cells were treated for 180 min with PBS (control; Cont.) alone, or LPS combined
with 20 μM of SB203580, PD98059, SP600125, or 100 nM 1,25(OH)2D3, and then harvested to conduct Western blot analyses of phosphorylated (p)-p38
(a), p-ERK (p42/44) (b), and p-JNK (p46/54) (c). Levels of p-p38, p-ERK, and p-JNK were respectively normalized to total levels of p38, ERK, and JNK, and
then quantified. Data are expressed as the mean± SEM (n= 5 in each group). *p< 0.05, ***p< 0.001 vs. the Cont.; +p< 0.05, ++p< 0.01, +++p< 0.001 vs. LPS
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may exacerbate neuronal damage due to the production
of inflammatory molecules. In this study, we used LPS
as a stimulant in neuron-glia cultures to initiate a neu-
roinflammatory response. The excessive production of
inflammatory molecules was used as an index of acti-
vated glia. In this model, LPS significantly and time-
dependently induced the production of inflammatory
molecules including NO (reflected by nitrite accumula-
tion), ROS, IL-6, and MIP-2 in cortical neuron-glia
cultures. Activation of the p38, ERK, and JNK MAPK
pathways is involved in LPS-initiated production of
inflammatory molecules. 1,25(OH)2D3 attenuated LPS-
induced nitrite accumulation, iNOS expression, and
ROS production in concentration-dependent manners.
LPS-induced production of IL-6 and MIP-2 was also
significantly reduced by 1,25(OH)2D3. Furthermore,
LPS-elicited phosphorylation of the p38, ERK, and JNK
MAPK pathways was decreased by 1,25(OH)2D3. These
results suggest that 1,25(OH)2D3 attenuates LPS-initiated
neuroinflammation through inhibiting MAPK activation
in neuron-glia cultures.
We previously demonstrated that astrocytes and
microglia are important early sources of proinflamma-
tory mediators in cerebrospinal fluid and brain tissues
during bacterial (Klebsiella pneumoniae) infection of the
central nervous system (CNS) [19]. Brain endothelial
cells and pericytes which surround endothelial cells not
only contribute to maintenance of the barrier function
of the blood–brain barrier but also are immunoactive
and can respond to LPS [20–22]. It is possible that LPS
may stimulate brain immune cells (e.g., astrocyte and
microglia) and other brain cells (e.g., pericytes, endothe-
lial cells, and fibroblasts) resulting in a complex cascade
of neuroinflammatory responses [20, 21, 26]. We
employed cortical neuron-glia cultures as an in vitro
model for mimicking the in vivo environment in which
neurons and glia can interact. The advantages of our
in vitro model were that (1) cultured cells can bypass
any possible physiological feedback interactions in vivo
to allow direct observation of LPS-induced neuroinflam-
mation in specific cell populations and (2) it provides a
simpler system to elucidate cellular mechanisms. How-
ever, its limitation is that cell cultures are simply an
attempt to provide a simulated microenvironment, and
cells are not in their normal physiological or original en-
vironment. The cortical neuron-glia cultures in this
study consisted of approximately 35 % neurons, 54 %
astrocytes, 6 % microglia, 4 % fibroblasts, and a small
percentage (<1 %) of other cells including oligodendro-
cytes, and endothelial cells. The low percentage of other
cell types may have been due to the fact that we dis-
sected cerebral cortices and carefully removed blood
vessel and meninges during our procedures to preparethe cortical neuron-glia cultures. It is possible that the
results of this study can be ascribed to complex interac-
tions between the different cell types found in the
cultures. However, considering the relatively poor re-
sponses of the small percentage of fibroblasts and other
cell types (oligodendrocytes and endothelial cells) to LPS,
we propose that glial cells (mainly astrocytes and micro-
glia) were the major responder cells in our culture system.
Glial cells play a role in immune surveillance under
normal conditions; however, after a brain injury or ex-
posure to inflammation, glial cells are activated. Under
neuroinflammation, glial cells become strongly over-
activated through a process that involves phosphoryl-
ation of downstream MAPK pathways (e.g., p38, ERK,
and JNK) and production of inflammatory molecules
[17]. Consistent with our results that treatment of cultured
neurons/glia with LPS significantly induced expression of
iNOS and the production of NO, ROS, IL-6, and MIP-2,
pharmacological inhibition of MAPK pathways by MAPK
inhibitors (SB 203580 for p38, PD98059 for ERK, and
SP600125 for JNK MAPK) partially attenuated LPS-
induced production of inflammatory molecules (ROS,
NO, iNOS, IL-6, and MIP-2). A Western blot analysis also
confirmed that treatment of cultured neurons-glia with
LPS significantly induced phosphorylation of the p38,
ERK, and JNK MAPK pathways, indicating that MAPK ac-
tivation is involved in LPS-induced neuroinflammation.
However, sustained overproduction of these inflammatory
molecules may further contribute to neuronal damage.
Therefore, inhibition of neuroinflammation has become a
promising therapeutic target for neuronal injuries.
A dietary vitamin D3 (cholecalciferol) deficiency may
lead to oxidative stress and elevation of iNOS expression
in the brain and further promote cognitive decline in
middle-aged and elderly adults [27]. It was reported that
inhibition of iNOS expression can cause improvements
in clinical signs observed in rats with experimentally
produced allergic encephalomyelitis (EAE) treated with
1,25(OH)2D3 [28]. 1,25(OH)2D3 also effectively attenuated
inflammatory cytokine expressions in the spinal cord and
ameliorated EAE in rats [29]. In that model, 1,25(OH)2D3
treatment significantly reduced Toll-like receptor 8
(TLR8) expression and TLR8 target gene expressions
(TNF-α and IL-1β) [29]. Additionally, 1,25(OH)2D3 pro-
vides neuroprotection against 1-methyl-4-1,2,3,6-tetrahy-
dropyridine (MPTP)-induced neuronal injury through
inhibition of glial activation and proinflammatory cytokine
expression [30]. Those findings suggest that 1,25(OH)2D3
has important roles in the brain. In this study, we found
that LPS-induced ROS production, nitrite accumulation,
iNOS expression, and IL-6 and MIP-2 production were
significantly reduced after treatment with 1,25(OH)2D3. It
is known that 1,25(OH)2D3 is one of the important nu-
clear steroid transcription regulators that can control
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known to exert its biological functions by directly influen-
cing cellular processes and also by influencing gene ex-
pressions through vitamin D response elements (VDREs).
We also found that levels of iNOS, IL-6, and MIP-2
mRNA expressions were also significantly attenuated by
1,25(OH)2D3, indicating that 1,25(OH)2D3 plays an im-
portant role in gene regulation. However, further studies
are required to elucidate the role of 1,25(OH)2D3 in LPS-
initiated gene expression.
The apparent lack of cell damage induced by LPS in our
cortical neuron-glia culture may have been due to regional
differences in the susceptibility to the concentration
(100 ng/ml or 0.1 μg/ml) of LPS in a shorter time (24 h)
period. Differential neurotoxicity in mixed neuron-glia
cultures from various brain regions after treatment with LPS
was demonstrated in a previous study [31] in which treat-
ment with LPS at an even higher concentration (1 μg/ml)
for a longer time (72 h) did not cause neurotoxicity in
cortical or hippocampal neuron-glia culture but caused
neurotoxicity in cultures derived from the mesencephalon.
In another study using mice cortical neuron-glia culture,
neurotoxicity was only observed with a longer exposure
time (36 h) when cultures were treated with LPS (1 μg/ml)
in combination with interferon (IFN)-γ (5 U/ml) [32]. The
concentration of 1,25(OH)2D3 we used in this study was
similar to that in previous reports [33, 34]. In order to ex-
clude the possibility that 1,25(OH)2D3 attenuated the
LPS-induced release of inflammatory molecules because
of 1,25(OH)2D3 toxicity, our results confirmed that
100 nM 1,25(OH)2D3 was not toxic to cultured neuron-
glia cells as revealed by the MTT and LDH assays as
well as immunocytochemistry. Because the concentra-
tion of 1,25(OH)2D3 used in our cultures effectively re-
duced LPS-induced neuroinflammation, we suggest
that 1,25(OH)2D3 supplementation may be a candidate
for prevention and treatment of neuroinflammation.
1,25(OH)2D3 is a neuro-immunomodulator involved in
various neurodegenerative and autoimmune diseases [3].
The neuroprotective effects of 1,25(OH)2D3 have been
reported in cultured hippocampal neurons against exci-
totoxic insults through reduced L-type calcium channel
expression [35] and against rotenone-induced neuro-
toxicity in human neuroblastoma cell line SH-SY5Y cells
by enhancing autophagy signaling [36]. Besides the direct
neuroprotective effects on neurons, 1,25(OH)2D3 also re-
duced neurotoxin-induced dopaminergic neuronal loss by
inhibiting of microglia activation and proinflammatory
cytokine expression [30]. It is known that 1,25(OH)2D3
acts via the vitamin D receptor (VDR), a member of the
steroid/thyroid hormone superfamily of transcription
factors, and the membrane-associated, rapid-response
steroid-binding receptor (MARRS), also known as
Erp57/Grp58 [3]. The VDR is expressed by glia [4] andneurons [37] in the brain, and not just those participat-
ing in the classic actions of vitamin D. The action of
1,25(OH)2D3 mediates its biological effects by binding
to the VDR, which then recruits cofactors to form a
transcriptional complex that binds to VDREs in the
promoter region of target genes to alter transcriptional
cascades within cells [2]. The non-classical action of
1,25(OH)2D3 is that it binds to the MARRS receptor,
located on the cell surface, initiating non-genomic ef-
fects [3]. A single-nucleotide polymorphism in the VDR
gene can influence the affinity of vitamin D to its re-
ceptor and thus may be related to neurodegenerative
diseases and neuronal damage by altering vitamin D-
mediated pathways [38, 39]. β-amyloid (Aβ) disrupts
the vitamin D-VDR pathway and results in iNOS ex-
pression in cortical neurons, whereas this effect can be
prevented by vitamin D [40]. Moreover, treatment with
vitamin D in that model protected neurons by preventing
cytotoxicity and apoptosis and also by upregulating the
VDR [41]. Those results suggest a potential role for vita-
min D-VDR-mediated mechanisms in AD. In this study,
we were interested in investigating how 1,25(OH)2D3
affected LPS-induced neuroinflammatory responses and
exploring whether the effects of 1,25(OH)2D3 were medi-
ated through MAPK signaling pathways. Involvement of
MAPK signaling pathways in the production of inflamma-
tory molecules in neurons and glial cells was previously
demonstrated [42–44]. The three major MAPK subfamilies
of p38, ERK, and JNK are phosphorylated in neurons and
glia following LPS treatment [45]. MAPKs are related to
LPS signaling in glial cells and lead to iNOS expression
and the production of NO and proinflammatory cytokines
[45–47]. The current results indicate that the phosphoryl-
ation of p38, ERK, and JNK MAPKs occurred after LPS
treatment. We demonstrated that 1,25(OH)2D3 decreased
the phosphorylation of p38, ERK, and JNK MAPKs as a
result of LPS. This is consistent with a previous report that
1,25(OH)2D3 reduced macrophage-induced release of
chemokines and cytokines by adipocytes and the chemo-
taxis of monocytes through inhibiting MAPK signaling
pathways [48]. Similarly, 1,25(OH)2D3 diminished LPS-
stimulated tumor necrosis factor (TNF)-α and IL-6 release
via inhibiting p38 phosphorylation in monocytes/
macrophages [49]. Our results suggest that the 1,25(OH)2D3-
mediated suppression of the production of neuroinflamma-
tory molecules may occur through inhibition of MAPK
pathways. However, further studies are required to better
understand the extents of1,25(OH)2D3’s anti-inflammatory
effects and its involvement in the progression of
neuroinflammation.
Conclusion
Our results suggest that 1,25(OH)2D3 significantly at-
tenuated the LPS-initiated production of inflammatory
Huang et al. Journal of Neuroinflammation  (2015) 12:147 Page 11 of 12molecules by inhibiting p38, ERK, and JNK MAPK signal-
ing in neuron-glia cultures. We suggest that 1,25(OH)2D3
might be an innovative approach to ameliorating neuro-
inflammation resulting from various neuronal injuries.
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